A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
Status:
Completed
Trial end date:
2001-11-01
Target enrollment:
Participant gender:
Summary
This study compares 2 different treatments administered to try to prevent serious bacterial
infections (such as pneumonia) in HIV-positive children. A combination of drugs (azithromycin
plus atovaquone) will be compared to sulfamethoxazole-trimethoprim (SMX/TMP) alone. This
study also evaluates the long-term safety and tolerance of these different drugs.
SMX/TMP is a commonly prescribed drug for the prevention of bacterial infections. However,
the combination of azithromycin and atovaquone may be safer and more effective than SMX/TMP.
This study compares the 2 treatments.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Glaxo Wellcome Pfizer
Treatments:
Atovaquone Azithromycin Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination